Microsoft Word Draft hydroxychloroquine covid-accepted (00000003)

Titles for figures 

Figure 1. Percentage of patients with PCR-positive nasopharyngeal samples from inclusion to 

day6 post-inclusion in COVID-19 patients treated with hydroxychloroquine and in COVID-

19 control patients. 

Figure 2. Percentage of patients with PCR-positive nasopharyngeal samples from inclusion to 

day6 post-inclusion in COVID-19 patients treated with hydroxychloroquine only, in COVID-

19 patients treated with hydroxychloroquine and azithomycin combination, and in COVID-19 

control patients. 

 

Acknowledgements: 

We thank Céline Boschi, Stéphanie Branger, Véronique Filosa, Géraldine Gonfier, Nadège 

Palmero, Magali Richez and all the clinical, technical and paramedical staffs of the 

hospitalization units and laboratories for their support in this difficult context. 

Funding source 

This work was supported by the French Government under the «  

Investissements d’avenir » (Investments for the Future) program managed by the  

Agence Nationale de la Recherche (ANR, fr: National Agency for Research),  

(reference: Méditerranée Infection 10-IAHU-03)